Tokyo, Japan - EXORPHIA Inc. (Headquarters: Chiyoda-ku, Tokyo; President & CEO: Koji Kuchiishi), Kyoritsu Holdings Inc. (Headquarters: Chiyoda-ku, Tokyo; President & CEO: Takaaki Takai), and Kyoritsu Seiyaku Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President & CEO: Takaaki Takai) have entered into a capital and business alliance agreement to jointly develop exosome-based therapeutics for pets.
Exosomes are nano-sized vesicles secreted by cells. It is known that exosomes derived from stem cells can aid recovery from diseases and injuries by delivering therapeutic agents to damaged tissues.
EXORPHIA is a biotech startup engaged in the research, development, and manufacturing of exosome-based therapeutics. Using its proprietary cell activation technology, EXORPHIA has successfully produced exosomes with potent anti-inflammatory and tissue regenerative properties.
Meanwhile, Kyoritsu Seiyaku, a subsidiary of Kyoritsu Holdings, develops, manufactures, and sells veterinary pharmaceuticals. In recent years, it has been actively investing in new fields related to veterinary medicine.
Through this partnership, EXORPHIA and Kyoritsu Seiyaku will combine EXORPHIA's exosome drug discovery platform technology with Kyoritsu Seiyaku's expertise in veterinary medicine to jointly develop exosome-based therapeutics for pets targeting conditions with high unmet medical needs, such as chronic kidney disease, heart disease, enteritis, and dermatitis.
EXORPHIA will leverage the knowledge and data obtained through this joint development for the development of exosome-based therapeutics for human use. Meanwhile, Kyoritsu Seiyaku, through Kyoritsu Holdings, will have exclusive distribution rights for the pet exosome therapeutics in Japan.
"Kyoritsu Seiyaku is a leading domestic company in veterinary pharmaceuticals with extensive knowledge and networks in pet medical care," said Koji Kuchiishi, President & CEO of EXORPHIA. "By utilizing our exosome drug discovery platform and collaborating with Kyoritsu Holdings and Kyoritsu Seiyaku, I am confident that we can contribute to veterinary medicine by creating new therapeutics for pets."
"We see great potential in EXORPHIA's innovative exosome technology," said Takaaki Takai, President & CEO of Kyoritsu Holdings and Kyoritsu Seiyaku. "By providing solutions that extend the healthy lifespan of pets and deepen the bond between owners and their pets, we will contribute to the realization of a society where animals and humans coexist."
Through this partnership, EXORPHIA, Kyoritsu Holdings, and Kyoritsu Seiyaku will accelerate the development of innovative exosome-based therapeutics that contribute to maintaining the health of pets.
[EXORPHIA Inc. Company Profile]
Company name: EXORPHIA INC.
Location: Otemachi Building 6F, 1-6-1 Otemachi, Chiyoda-ku, Tokyo
Establishment: May 2019
Representative: Koji Kuchiishi, President and CEO
Business: Research and development, manufacturing and sales of human cell-derived exosome medicines
[Company profile of Kyoritsu Holdings Corporation]
Company name: Kyoritsu Holdings Co.
Location: Kudan Kaikan Terrace, 1-6-5 Kudan Minami, Chiyoda-ku, Tokyo
Establishment: September 2015
Representative: Takaaki Takai, President and CEO
Business: Strategic planning and management of the Kyoritsu Group, optimal allocation of group management resources, consolidated group financial management, etc.
[Company profile of Kyoritsu Pharmaceutical Co.]
Company name: Kyoritsu Pharmaceutical Co.
Location: Kudan Kaikan Terrace, 1-6-5 Kudan Minami, Chiyoda-ku, Tokyo
Establishment: May 1955
Representative: Takaaki Takai, President and Representative Director
Business: Development, manufacture, sale, import and export of veterinary drugs, etc.
For inquiries regarding this press release, please contact:
EXORPHIA Inc. Public Relations
Email: pr@exorphia.com
